CommercialAdministrativeLow impact
07.13.05m, Photodynamic Therapy (PDT) Using Verteporfin (Visudyne®)
Independence Blue Cross·Ophthalmology·Pharmacy
Effective date
Mar 4, 2026
We identified it
Jun 19, 2026
Summary
The policy for Photodynamic Therapy (PDT) using Verteporfin (Visudyne®) has been reissued with an effective date of March 4, 2026. This is a reissue of an existing policy rather than new coverage changes, maintaining current billing and coverage guidelines for this specialized eye treatment.
Action Required
By March 4, 2026: Review updated policy document at provided URL to confirm no changes to current PDT billing procedures. Ophthalmology billing staff should verify existing prior authorization and documentation requirements remain unchanged.